Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insecticidal Effects of Plasma Treated Water.
Ten Bosch L, Köhler R, Ortmann R, Wieneke S, Viöl W. Ten Bosch L, et al. Among authors: ortmann r. Int J Environ Res Public Health. 2017 Nov 27;14(12):1460. doi: 10.3390/ijerph14121460. Int J Environ Res Public Health. 2017. PMID: 29186877 Free PMC article.
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
Smolen JS, Xie L, Jia B, Taylor PC, Burmester G, Tanaka Y, Elias A, Cardoso A, Ortmann R, Walls C, Dougados M. Smolen JS, et al. Among authors: ortmann r. Rheumatology (Oxford). 2021 May 14;60(5):2256-2266. doi: 10.1093/rheumatology/keaa576. Rheumatology (Oxford). 2021. PMID: 33200220 Free PMC article. Clinical Trial.
COVID-19 and investor behavior.
Ortmann R, Pelster M, Wengerek ST. Ortmann R, et al. Financ Res Lett. 2020 Nov;37:101717. doi: 10.1016/j.frl.2020.101717. Epub 2020 Aug 8. Financ Res Lett. 2020. PMID: 32837386 Free PMC article.
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC. Tanaka Y, et al. Among authors: ortmann ra. Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30. Ann Rheum Dis. 2019. PMID: 31040122 Free PMC article. Clinical Trial.
FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity.
Wiesner J, Ziemann C, Hintz M, Reichenberg A, Ortmann R, Schlitzer M, Fuhst R, Timmesfeld N, Vilcinskas A, Jomaa H. Wiesner J, et al. Among authors: ortmann r. Virulence. 2016 Aug 17;7(6):718-28. doi: 10.1080/21505594.2016.1195537. Epub 2016 Jun 3. Virulence. 2016. PMID: 27260413 Free PMC article.
111 results